Frederick Frank, a veteran biotech banker from Lehman Brothers, will act as an adviser to Global Life Science Ventures, the Munich-based venture capital firm, on developing portfolio companies bought from its new €143m ($162m) fund.
Frank, who became a partner at Lehman in 1969, will continue as a director and vice-chairman of the bank's US-based biotechnology investment banking division.